Roivant launches new startup Sinovant Sciences in China

19 July 2018 (Last Updated July 19th, 2018 12:38)

Global healthcare company Roivant Sciences has launched a spin-off called Sinovant Sciences in Shanghai, China, to primarily develop innovative therapeutics through biomedical research and development (R&D).

Global healthcare company Roivant Sciences has launched a spin-off called Sinovant Sciences in Shanghai, China, to primarily develop innovative therapeutics through biomedical research and development (R&D).

Sinovant is also backed by Chinese private equity firm CITICPE.

Sinovant has a pipeline of 11 investigational drugs intended for Greater China and other Asian markets. The newest additions to the pipeline are derazantinib, lefamulin and RVT-802.

The formation of the pipeline, as well as the creation of a senior leadership team, was the result of Roivant’s support.

Derazantinib is an inhibitor of fibroblast growth factor receptor (FGFR) and is currently in Phase III clinical development to treat intrahepatic cholangiocarcinoma (iCCA), a type of liver cancer with high incidence in Greater China that has no approved therapies.

Lefamulin is an antibiotic, which is expected to offer a first-line empiric monotherapy for community-acquired bacterial pneumonia (CABP) because of its low incidence of cross-resistance and low susceptibility to develop bacterial resistance.

“Roivant Sciences has launched a spin-off called Sinovant Sciences in Shanghai, China to primarily develop innovative therapeutics.”

The therapeutic already completed assessment in two Phase III trials for the treatment of CABP. It was recently granted qualified infectious disease product designation from the US Food and Drug Administration (FDA) and a new drug application submission is preparing to be launched in the US and Europe.

RVT-802 is a tissue-based regenerative therapy being developed for treating primary immune deficiency caused due to congenital athymia in complete DiGeorge Anomaly, a fatal paediatric disorder.

The investigational candidate has FDA breakthrough therapy, rare paediatric disease, regenerative medicine advanced therapy (RMAT) and orphan drug designations.

Sinovant also announced it has formed an alliance with Renexxion to obtain the Chinese rights for an investigational gastrointestinal prokinetic called naronapride.

Initially, Sinovant intends to develop naronapride for the treatment of irritable bowel syndrome with constipation (IBS-C) and then plans to extend into other gastrointestinal conditions.

Furthermore, Sinovant has collaborated with a public health non-profit organisation China Liver Health to boost the availability of new medicines for liver and infectious diseases in the country.